Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.34 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | PTPRG | P23470 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831545 | 0.92 | KMT2A (0.40) | CYP2C8CCR2MCL1PPARGKMT2A | |
| SCHEMBL832603 | 0.90 | CYP2C8 (0.40) | CYP2C8MCL1KMT2ARCE1MEN1 | |
| SCHEMBL10260727 | 0.88 | PPARG (0.38) | CYP2C8CCR2MCL1PPARGKMT2A | |
| SCHEMBL862469 | 0.88 | PPARG (0.36) | CYP2C8MCL1PPARGKMT2AMEN1 | |
| SCHEMBL862475 | 0.88 | PPARG (0.36) | CYP2C8CCR2MCL1PPARGKMT2A | |
| SCHEMBL10257730 | 0.87 | PPARG (0.35) | CYP2C8CCR2MCL1PPARGKMT2A | |
| SCHEMBL12665251 | 0.87 | CYP2C8 (0.49) | CYP2C8CCR2KMT2ARCE1MEN1 | |
| SCHEMBL861876 | 0.86 | PPARG (0.35) | CYP2C8MCL1PPARGKMT2AMEN1 | |
| SCHEMBL862413 | 0.85 | PPARG (0.43) | CYP2C8MCL1PPARGKMT2AMEN1 | |
| SCHEMBL831718 | 0.85 | KMT2A (0.40) | CYP2C8MCL1KMT2ARCE1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | CYP2C8 847/4885CCR2 106/4885MCL1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.